Literature DB >> 25669873

Delayed cardiac dysrhythmias after fingolimod administration.

Jamie M Rosini1, Suraj Rajasimhan2, Shawn E Fellows3, Jason T Nomura4.   

Abstract

A 51-year-old woman with relapsing-remitting multiple sclerosis was initiated on fingolimod. She developed a Mobitz Type I (Wenckebach)second-degree atrioventricular (AV) heart block during the initial 6-hour monitoring. She was transferred to the emergency department for further monitoring, where she went into a junctional tachycardia then went back into a Mobitz Type I AV block. The patient was symptomatic with a heart rate nadir of 38 beats per minute and treated with atropine. Junctional tachycardia has not been previously reported with fingolimod use. Patients may require extended cardiac monitoring after fingolimod administration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25669873     DOI: 10.1016/j.ajem.2014.12.037

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  5 in total

1.  Ziprosidone-Induced Transient Agranulocytosis; Delayed Onset of Cardiac Adverse Effects with Fingolimod; Telmisartan-Induced Myotoxicity; Severe Dilated Cardiomyopathy Induced by Adalimumab and Ustekinumab.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2015-11-19

Review 2.  Regulation of sarcoplasmic reticulum Ca2+ release by serine-threonine phosphatases in the heart.

Authors:  Dmitry Terentyev; Shanna Hamilton
Journal:  J Mol Cell Cardiol       Date:  2016-08-29       Impact factor: 5.000

Review 3.  Roles and regulation of protein phosphatase 2A (PP2A) in the heart.

Authors:  Ellen R Lubbers; Peter J Mohler
Journal:  J Mol Cell Cardiol       Date:  2016-11-08       Impact factor: 5.000

4.  Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

Authors:  Volker Limmroth; Tjalf Ziemssen; Michael Lang; Stephan Richter; Bert Wagner; Judith Haas; Stephan Schmidt; Kathrin Gerbershagen; Christoph Lassek; Luisa Klotz; Olaf Hoffmann; Christian Albert; Katrin Schuh; Monika Baier-Ebert; Guillaume Wendt; Heinke Schieb; Susanne Hoyer; Ralf Dechend; Wilhelm Haverkamp
Journal:  BMC Neurol       Date:  2017-01-18       Impact factor: 2.474

Review 5.  Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies.

Authors:  Oliver Findling; Larissa Hauer; Thomas Pezawas; Paulus S Rommer; Walter Struhal; Johann Sellner
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.